There is no fixed time limit for meloxicam. Many people take it for months or even years to manage chronic conditions like osteoarthritis or rheumatoid arthritis. However, the FDA’s guiding principle is to use the lowest effective dose for the shortest duration that meets your treatment goals, because the risk of serious side effects rises the longer you take it.
In clinical trials, meloxicam was given to 661 patients for at least six months and 312 patients for at least one year. That means long-term use has been studied, but it does come with trade-offs your body accumulates over time.
Why Duration Matters
Meloxicam belongs to the NSAID family and works by blocking an enzyme involved in inflammation and pain signaling. It preferentially targets the version of that enzyme most active during inflammation (COX-2) while having less effect on the version that protects your stomach lining (COX-1). This selectivity is why meloxicam tends to be gentler on the stomach than older NSAIDs like naproxen or ibuprofen, but “gentler” is not the same as risk-free.
The core issue with long-term use is that several categories of risk, including stomach, kidney, heart, and liver problems, don’t stay constant. They climb with time. So while there’s no calendar date where meloxicam “expires” as a treatment option, your prescriber should periodically reassess whether the benefits still outweigh those rising risks.
Stomach and Digestive Risks Over Time
This is the best-documented risk with extended NSAID use, and the numbers are specific. Among patients treated for three to six months, roughly 1% develop upper gastrointestinal ulcers, significant bleeding, or perforation. For patients treated for one year, that figure rises to 2% to 4%. These trends continue climbing with longer use.
At the lower 7.5 mg daily dose, meloxicam performs significantly better than several other NSAIDs. A large analysis of over 24,000 patients found a 0.03% risk of serious upper GI events at that dose, which was meaningfully lower than the rates seen with diclofenac, naproxen, or piroxicam. At 15 mg daily, the advantage narrows. About a quarter of patients in six-month trials reported some form of GI discomfort (nausea, indigestion, or similar symptoms), regardless of dose. Most of these were mild, but they illustrate why stomach issues are the most common reason people stop taking the drug.
Kidney Concerns With Chronic Use
Your kidneys rely on certain chemical signals to maintain blood flow and filter waste properly. NSAIDs, including meloxicam, suppress those signals. In a healthy person with normal hydration, the kidneys compensate without much trouble. But when the kidneys are already under stress, from heart failure, liver disease, dehydration, or simply aging, blocking those protective signals can tip the balance toward damage.
Short-term use rarely causes kidney problems in otherwise healthy adults. Long-term daily use, however, can lead to a slow, progressive form of kidney damage involving scarring and reduced function. In more severe cases, tissue death in part of the kidney (papillary necrosis) has been reported with various NSAIDs. The risk is highest in people who are older, have pre-existing kidney disease, take blood pressure medications, or are chronically dehydrated. If you’re on meloxicam for more than a few months, periodic blood work to check kidney function is standard practice.
Heart and Stroke Risk
All NSAIDs carry a cardiovascular warning. For short courses of less than a month, the added risk of heart attack or stroke is extremely small. For people who already have heart disease or who need high-dose, long-term treatment, the increased risk becomes more meaningful. The FDA requires a boxed warning on all prescription NSAIDs about this, and meloxicam is no exception. If you have established cardiovascular disease or multiple risk factors, your prescriber will weigh this carefully when deciding whether to continue meloxicam beyond the short term.
Liver Effects
Liver injury from meloxicam is uncommon and generally reversible. In studies, up to 7% of patients showed at least a temporary bump in liver enzymes, the blood markers that indicate liver stress. Only about 1% had elevations high enough to be clinically notable (more than three times the normal upper limit). When those patients stopped taking meloxicam, recovery was typically rapid. No fatal or chronic liver injury cases have been linked to the drug, which makes it one of the safer NSAIDs in this regard. Still, if you’re taking it long-term, occasional liver function checks are reasonable.
The 7.5 mg vs. 15 mg Question
The recommended starting and maintenance dose for both osteoarthritis and rheumatoid arthritis is 7.5 mg once daily. Some people get additional benefit from increasing to 15 mg, which is the maximum allowed daily dose. Doses above 15 mg have been associated with a higher rate of serious GI events and are not recommended.
If you’re planning to stay on meloxicam for an extended period, the 7.5 mg dose carries a more favorable safety profile across the board. The clinical trials that ran for six months and one year used both doses, and GI symptom rates were similar between them (around 25%), but the serious complication risk at 7.5 mg was notably lower in large pooled analyses. Starting low and staying low is the general strategy for long-term use.
Use in Children
Meloxicam is approved for juvenile idiopathic arthritis in children ages 2 and older. A 12-month clinical trial found that its safety and effectiveness in children were comparable to naproxen, with no meaningful differences in side effects or abnormal lab results between the groups. About 81% of children completed the full year of treatment. So while long-term pediatric use is supported by evidence, the same principle of using the lowest effective dose applies.
Interactions That Affect Long-Term Safety
If you take low-dose aspirin for heart protection, adding meloxicam can interfere with aspirin’s ability to prevent blood clots. Clinical observations have linked concurrent use of these two drugs to reduced aspirin effectiveness, possibly because they compete for the same binding sites on platelets. Separating the timing of each dose (taking them several hours apart) may reduce this interaction. The same caution applies to blood thinners, where combining them with meloxicam increases bleeding risk, especially over months of overlapping use.
What Long-Term Use Actually Looks Like
In practice, many people with osteoarthritis or rheumatoid arthritis take meloxicam for years. This is not inherently dangerous, but it does require active management. That means periodic blood work to monitor kidney and liver function, attention to any new digestive symptoms, and honest reassessment of whether the drug is still doing enough to justify continued use. Some people find that their condition improves enough to try stepping down to an as-needed schedule, while others need daily coverage indefinitely.
The risks are real but graded. A 45-year-old with osteoarthritis and no other health problems faces a very different risk calculation at one year than a 70-year-old with high blood pressure and mild kidney impairment. Your individual timeline on meloxicam depends less on the drug itself and more on what else is going on in your body.